About FDALive
At FDALive, we are always interested in hearing from our customers.
FDALive Mailing Address:
11800 Nebel Street
Rockville, Maryland 20852-2508
Get Directions On Google Maps
View Larger Map
Telephone
301.984.0001
Fax
301.984.8954
E-mail:
FDALive General Information - info@fdalive.com
FDALive Sales - sales@fdalive.com
FDALive Technical Support - support@fdalive.com
Upcoming Meetings
Recent Meetings
Cellular, Tissue, and Gene Therapies AdComm
Meeting Date: 4/15/21-4/15/21
Meeting Details:
The Committee will meet in open session to discuss biologics license application (BLA) 125734 for donislecel (purified allogeneic deceased donor pancreas derived Islets of Langerhans). The applicant, CellTrans, Inc., has requested an indication for the “treatment of brittle Type 1 diabetes mellitus (T1D).” The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
Location: | Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. | Related News Links: | Not Available |
Time: | 10:00AM-6:00PM | ||
Materials: | |||
Circulatory System Devices Panel of the MDAC
Sponsor: TransMedics, Inc
Meeting Date: 4/6/21-4/6/21
Meeting Details:
The committee will discuss, make recommendations, and vote on information regarding the premarket approval application for the TransMedics Organ Care System (OCS) Heart, by TransMedics, Inc. The proposed Indication for Use for the TransMedics OCS Heart, is as follows: The TransMedics Organ Care System (OCS) Heart System is a portable extracorporeal heart perfusion and monitoring system indicated for the resuscitation, preservation, and assessment of donor hearts in a near-physiologic, normothermic, and beating state intended for a potential transplant recipient. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
Location: | The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. | Related News Links: | Not Available |
Time: | 9:00AM-6:00PM | ||
Materials: | |||
Joint Meeting of the Arthritis Advisory Committee and the DSaRM
Meeting Date: 3/24/21-3/25/21
Meeting Details:
The committees will discuss biologics license application (BLA) 761130, tanezumab subcutaneous injection, submitted by Pfizer Inc., for the proposed indication of relief of signs and symptoms of moderate to severe osteoarthritis in adult patients for whom use of other analgesics is ineffective or not appropriate. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
Location: | Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. | Related News Links: | Not Available |
Time: | 9:00AM-4:30PM | ||
Materials: | |||
General and Plastic Surgery Devices Panel of the MDAC
Meeting Date: 3/23/21-3/23/21
Meeting Details:
The committee will discuss and make recommendations regarding the benefits and risks of dermal fillers concerning the following topics: (1) risks associated with intravascular injection of dermal fillers and (2) patient preference and informed decision making. FDA is convening this meeting to seek expert opinion on the clinical evaluation and regulation of dermal filler products. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.
Location: | Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. | Related News Links: | Not Available |
Time: | 9:00AM-6:00PM | ||
Materials: | |||